RxDoctor Payments Data

Marc Sonenshine, MD

Gastroenterology · Atlanta, GANPI 1376681411

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $125,649 of the $200,892 with a category attached, or 62.5%. 48 manufacturers reported payments, led by AbbVie at 54.0% of the total. Reporting peaked in 2019 at $80,457 and has fallen 80.3% since, to $15,859 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$200,892in general payments, 2019–2025

Across 988 payments — averaging $203.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$109K
  • Phathom Pharmaceuticals, Inc.$36K
  • Endo Pharmaceuticals Inc.$13K
  • Amgen$9K
  • Janssen Scientific Affairs, LLC$8K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$6K
  • plus $20K from 42 others

What the payments were for

  • Consulting fees$30,12015%
  • Speaking & faculty fees$125,64963%
  • Travel & lodging$27,19514%
  • Food & beverage$17,7179%
  • Education$2120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,892 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$132,138
Medicare patients
599
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$92,632
LinzessLinaclotide53$56,437
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates189$12,623
Pantoprazole Sodium570$8,011
Dexlansoprazole DrDexlansoprazole14$5,780
Esomeprazole Magnesium43$1,951
Rabeprazole Sodium46$1,696
Famotidine117$1,549
CholestyramineCholestyramine (With Sugar)19$1,219
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl55$897
Dicyclomine Hcl49$658
Omeprazole60$457
Ondansetron OdtOndansetron49$389
Sulfasalazine11$353
Amitriptyline Hcl19$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$108,502$149,06972 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →